Design Therapeutics reported a net loss of $16.0 million for the fourth quarter of 2025 as it continues to advance its GeneTAC clinical portfolio. The company maintains a strong liquidity position with $219.8 million in cash and securities, providing an operating runway into 2029.
Ongoing Phase 1/2 MAD trial for DT-216P2 in Friedreich Ataxia with data update expected in H2 2026.
Phase 2 biomarker trial for DT-168 in FECD is ongoing with data anticipated in H2 2026.
Patient dosing for DT-818 in Myotonic Dystrophy Type-1 is expected to begin in H1 2026.
Cash runway is projected to support planned operations into 2029.
Design Therapeutics expects its current cash position to fund operations into 2029 and anticipates several clinical milestones in 2026.
Analyze how earnings announcements historically affect stock price performance